The Clinical Core will provide biological specimens, data management and statistical expertise to support research within this U19. The Clinical Core will build upon a rich and highly productive set of existing, NIH supported cohorts and infrastructure to ensure that well-characterized participants who meet the criteria outlined in each of the projects are available for proposed investigations. Using an infrastructure that is already in place and operational, all of the procedures necessary to collect and characterize clinical biological specimens will be provided by the Core, including phlebotomy, leukapheresis, gut biopsy, lymph node biopsy and/or bone marrow biopsy. The Clinical Core will also encompass an Analysis sub-core, which will provide centralized data management and biostatistical analysis support across projects. The Clinical Core has four specific aims: (1) to recruit and follow study participants required to perform the science outlined in the research projects of this U19 program;(2) to provide biological specimens from well characterized participants to support all projects performing studies in humans;(3) to provide data management services, including developing a central database for the U19 network and a data sharing plan, and;(4) to provide statistical support for every stage of all projects. The Clinical Core has overall goals of integrating investigations in this U19, enhancing interactions between projects and achieving a true multidisciplinary approach to translational investigation. To achieve these goals, the Core will: (1) insure that the molecular, cellular, and clinical measurements outlined in each of the projects are performed on the same subjects and at the same time points, when possible;(2) provide database support so that the data generated in the Collaboratory in each of the projects and cores are managed centrally in an integrated fashion that facilitates cross-project investigations;(3) provide biostatistical support to each project to ensure consistent and rigorous analysis approaches;and (4) provide cross-disciplinary expertise integrating clinical and biological data with a team that is highly experienced in this process.
The Clinical Core is critical in supporting the research projects in this proposal that study human subjects. It will provide a central resource for enrolling study participants, and carrying out all the procedures to provide blood and other tissues for the research projects. It will also provide data management and statistical expertise that will integrate data across projects as well as supporting data analysis work for each project.
|Okoye, Afam A; Hansen, Scott G; Vaidya, Mukta et al. (2018) Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat Med 24:1430-1440|
|Winckelmann, Anni; Morcilla, Vincent; Shao, Wei et al. (2018) Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals. AIDS 32:1793-1802|
|Wykes, Michelle N; Lewin, Sharon R (2018) Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18:91-104|
|Lee, Sulggi A; Elliott, Julian H; McMahon, James et al. (2018) Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. Clin Pharmacol Ther :|
|Kumar, Nitasha A; van der Sluis, Renee M; Mota, Talia et al. (2018) Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4+ T Cells. J Immunol 201:1468-1477|
|Walters, Lucy C; Harlos, Karl; Brackenridge, Simon et al. (2018) Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nat Commun 9:3137|
|Adland, Emily; Hill, Matilda; Lavandier, Nora et al. (2018) Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. J Virol 92:|
|Boyer, Zoe; Palmer, Sarah (2018) Targeting Immune Checkpoint Molecules to Eliminate Latent HIV. Front Immunol 9:2339|
|Wang, Chia-Ching; Thanh, Cassandra; Gibson, Erica A et al. (2018) Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. Blood Adv 2:3479-3482|
|Reeves, Daniel B; Duke, Elizabeth R; Wagner, Thor A et al. (2018) A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nat Commun 9:4811|
Showing the most recent 10 out of 190 publications